# R1 Stage 5C — Reviewer A amendment, PubChem AIDs 851 and 856

**Date recorded:** 2026-10-14  
**Pair key:** `PUBCHEM::NP_004221::IC50::851::856`  
**Position in frozen 43-pair registry:** row 29 (called “Pair 1” in the conversational review sequence)  
**Review status:** AMENDED PRELIMINARY HUMAN REVIEW; NOT BLINDED; NOT FINAL CONSENSUS  
**Reviewer identifier:** Reviewer A (identity and qualification information kept separately, pending declaration)

## Original choices (retained without alteration)

| Dimension | Original selection |
|---|---|
| Measurement reuse | `CONFIRMED_DISTINCT` |
| Experimental execution | `DISTINCT_EXECUTION` |
| Discovery-program lineage | `DISTINCT_PROGRAMS` |

## Reviewer-requested correction (verbatim decision preserved)

> My decision: I agree with changing the three selections to: `UNRESOLVED / UNRESOLVED / SHARED_PROGRAM`.

The reviewer explains that published assay descriptions do not establish measurement reuse or separate experimental runs and identifies PubChem AID 1657 as additional support for a shared S1P2 probe-development project. These decisions were amended in response to AI-assisted feedback in the same conversation and **must not be represented as blind or independent of prior AI review**.

| Evidence dimension | Amended reviewer decision | Interpretation constraint |
|---|---|---|
| Measurement reuse | `UNRESOLVED` | Distinct readouts/stimuli do not alone establish raw measurement independence |
| Experimental execution | `UNRESOLVED` | No affirmative documentation of plate/run dates or execution independence |
| Discovery-program lineage | `SHARED_PROGRAM` | AID 1657 expressly lists AID 736 primary HTS, AID 856 counterscreening and AID 851 titration under one S1P2 probe-development effort |

## Primary source records and checks

- **AID 851:** https://pubchem.ncbi.nlm.nih.gov/bioassay/851 — S1P2 antagonist concentration response; contains grant 1 R03 MH076533-01, PI Germana Sanna, and references AIDs 736 and 856.
- **AID 856:** https://pubchem.ncbi.nlm.nih.gov/bioassay/856 — CRE-BLA counterscreen; same grant and PI as AID 851, reciprocal AID cross-reference.
- **AID 1657:** https://pubchem.ncbi.nlm.nih.gov/bioassay/1657 — *Summary of probe development efforts to identify antagonists of S1P2*, clearly states primary high-throughput screening AID 736, subsequent AID 856 counterscreening and AID 851 titration in one project.

**Metadata discrepancy to preserve:** AID 1657 displays “Grant Proposal Number: MH076534-01,” while AIDs 851 and 856 display “1 R03 MH076533-01.” The program linkage is directly supported by AID 1657’s descriptions and not contingent on grant numbers matching. No claim is made that the different grant numbers are typographical errors.

## Interpretation and readiness

Under the *strict program-disjoint* operational criterion, affirmative shared-project evidence is sufficient to mark **program-nonindependent** *conditional on that definition*, even though measurement reuse and separate physical execution remain **unresolved**. This is not evidence of copied raw data.

The archived compatibility status (INCOMPATIBLE_FOR_INTENDED_ESTIMAND) is **a separate historical classification** and has not been re-adjudicated as part of this amendment.

**Outstanding before final validation:** reviewer expertise/eligibility and conflict declaration; independent second human review; assessment of positive and negative known-provenance controls; final adjudication with documented reconciliation. No chance-corrected inter-rater reliability is estimable from this single amended record.

**Dataset governance:** The original frozen 43-pair CSV must not be overwritten. Only add this amendment as a new dated review record; do not alter historical conclusions or model/network counts before independent validation.